TY - JOUR
T1 - Papillary Renal Cell Carcinoma
T2 - Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
AU - Massari, Francesco
AU - Mollica, Veronica
AU - Fiala, Ondrej
AU - De Giorgi, Ugo
AU - Kucharz, Jakub
AU - Vitale, Maria Giuseppa
AU - Molina-Cerrillo, Javier
AU - Facchini, Gaetano
AU - Seront, Emmanuel
AU - Lenci, Edoardo
AU - Bourlon, Maria T.
AU - Carrozza, Francesco
AU - Pichler, Renate
AU - Lolli, Cristian
AU - Myint, Zin W.
AU - Kanesvaran, Ravindran
AU - Torniai, Mariangela
AU - Rescigno, Pasquale
AU - Gomez de Liaño, Alfonso
AU - Zakopoulou, Roubini
AU - Buti, Sebastiano
AU - Porta, Camillo
AU - Grande, Enrique
AU - Santoni, Matteo
N1 - Publisher Copyright:
Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.
PY - 2024/10/1
Y1 - 2024/10/1
N2 - BACKGROUND AND OBJECTIVE: Papillary renal cell carcinoma (pRCC) is the most frequent histological subtype of non-clear cell RCC (nccRCC). Owing to the heterogeneity of nccRCC, patients are often excluded from large phase 3 trials focused on clear cell RCC, so treatment options for nccRCC remain limited. Our aim was to investigate the efficacy of first-line treatment with tyrosine kinase inhibitors (TKIs) or immuno-oncology (IO)-based combinations in patients with pRCC. METHODS: We performed a multicenter retrospective analysis of real-world data collected for patients with advanced pRCC treated in 40 centers in 12 countries as part of the ARON-1 project (NCT05287464). The primary endpoints were overall survival (OS), progression-free survival (PFS), the overall response rate (ORR), and time to second progression (PFS2). OS, PFS, and PFS2 were estimated using the Kaplan-Meier method and results were compared between the treatment groups using a log-rank test. Univariate and multivariable analyses were carried out using Cox proportional-hazard models. KEY FINDINGS AND LIMITATIONS: We included 200 patients with metastatic pRCC, of whom 73 were treated with IO-based combinations and 127 with TKIs. Median OS was 22.5 mo in the TKI group 28.8 mo in the IO group (p = 0.081). Median PFS was 6.4 mo in the TKI group and 17.4 mo in the IO group (p < 0.001). The ORR was higher in the IO group than in the TKI group (41% vs 27%; p = 0.037). CONCLUSIONS AND CLINICAL IMPLICATIONS: Our results show that IO-based combinations have superior efficacy outcomes to TKIs for first-line treatment of metastatic pRCC. PATIENT SUMMARY: The ARON-1 project collects clinical data for patients with kidney cancer treated in multiple centers worldwide to assess outcomes in the real-world setting. We analyzed data for patients with metastatic kidney cancer of a specific subtype to evaluate the efficacy of different first-line treatments. Patients treated with immune-based combinations had better outcomes than patients treated with tyrosine kinase inhibitors.
AB - BACKGROUND AND OBJECTIVE: Papillary renal cell carcinoma (pRCC) is the most frequent histological subtype of non-clear cell RCC (nccRCC). Owing to the heterogeneity of nccRCC, patients are often excluded from large phase 3 trials focused on clear cell RCC, so treatment options for nccRCC remain limited. Our aim was to investigate the efficacy of first-line treatment with tyrosine kinase inhibitors (TKIs) or immuno-oncology (IO)-based combinations in patients with pRCC. METHODS: We performed a multicenter retrospective analysis of real-world data collected for patients with advanced pRCC treated in 40 centers in 12 countries as part of the ARON-1 project (NCT05287464). The primary endpoints were overall survival (OS), progression-free survival (PFS), the overall response rate (ORR), and time to second progression (PFS2). OS, PFS, and PFS2 were estimated using the Kaplan-Meier method and results were compared between the treatment groups using a log-rank test. Univariate and multivariable analyses were carried out using Cox proportional-hazard models. KEY FINDINGS AND LIMITATIONS: We included 200 patients with metastatic pRCC, of whom 73 were treated with IO-based combinations and 127 with TKIs. Median OS was 22.5 mo in the TKI group 28.8 mo in the IO group (p = 0.081). Median PFS was 6.4 mo in the TKI group and 17.4 mo in the IO group (p < 0.001). The ORR was higher in the IO group than in the TKI group (41% vs 27%; p = 0.037). CONCLUSIONS AND CLINICAL IMPLICATIONS: Our results show that IO-based combinations have superior efficacy outcomes to TKIs for first-line treatment of metastatic pRCC. PATIENT SUMMARY: The ARON-1 project collects clinical data for patients with kidney cancer treated in multiple centers worldwide to assess outcomes in the real-world setting. We analyzed data for patients with metastatic kidney cancer of a specific subtype to evaluate the efficacy of different first-line treatments. Patients treated with immune-based combinations had better outcomes than patients treated with tyrosine kinase inhibitors.
KW - ARON-1
KW - Immuno-oncology combinations
KW - Immunotherapy
KW - Papillary renal cell carcinoma
KW - Survival
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85201193925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85201193925&partnerID=8YFLogxK
U2 - 10.1016/j.euo.2024.03.011
DO - 10.1016/j.euo.2024.03.011
M3 - Article
C2 - 38575409
AN - SCOPUS:85201193925
VL - 7
SP - 1123
EP - 1131
JO - European urology oncology
JF - European urology oncology
IS - 5
ER -
